A clinical-stage biotech developing nasal sprays and pills for anxiety, depression, and PTSD—think of it as a startup trying to prove its drugs work before any are sold.
No revenue from products; the company burns cash, with net losses of USD 0.07B in fiscal 2026 and USD 0.05B in 2025. Money comes only from investors, not operations.
No approved drugs or sales, so any protection is speculative. Competitors like Sage Therapeutics and Intra-Cellular Therapies already have marketed CNS treatments, and VistaGen's pipeline is unproven—nothing stops them from dominating.
Key events, in time order
None yet
None yet
No comments yet.
Facts and opinions separated · All items sourced · Not investment advice
